These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 23880197

  • 1. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P.
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 4. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [Abstract] [Full Text] [Related]

  • 6. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
    Averna M, Zaninelli A, Le Grazie C, Gensini GF.
    J Clin Lipidol; 2010 Dec; 4(4):272-8. PubMed ID: 21122660
    [Abstract] [Full Text] [Related]

  • 7. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS.
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [Abstract] [Full Text] [Related]

  • 8. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, Massaad R, Vandormael K.
    Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B, Ezetimibe Study Group.
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [Abstract] [Full Text] [Related]

  • 10. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M, Taggart W, Dong Q, Lin J, Shah A, Brudi P.
    J Clin Lipidol; 2011 Feb; 5(3):179-187. PubMed ID: 21600523
    [Abstract] [Full Text] [Related]

  • 11. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM.
    J Clin Lipidol; 2011 Feb; 5(6):474-82. PubMed ID: 22108151
    [Abstract] [Full Text] [Related]

  • 12. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.
    J Clin Lipidol; 2013 Feb; 7(4):292-303. PubMed ID: 23890516
    [Abstract] [Full Text] [Related]

  • 13. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P.
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [Abstract] [Full Text] [Related]

  • 14. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
    Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB.
    Vasc Health Risk Manag; 2014 Apr; 10():279-90. PubMed ID: 24855368
    [Abstract] [Full Text] [Related]

  • 15. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
    Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C.
    Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
    [Abstract] [Full Text] [Related]

  • 16. Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.
    Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, Rosenberg E, Tershakovec AM.
    J Clin Lipidol; 2008 Dec; 2(6):436-46. PubMed ID: 21291777
    [Abstract] [Full Text] [Related]

  • 17. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB.
    MedGenMed; 2005 Jul 14; 7(3):3. PubMed ID: 16369229
    [Abstract] [Full Text] [Related]

  • 18. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P.
    Cardiovasc Ther; 2012 Apr 14; 30(2):61-74. PubMed ID: 20626402
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
    Constance C, Westphal S, Chung N, Lund M, McCrary Sisk C, Johnson-Levonas AO, Massaad R, Allen C.
    Diabetes Obes Metab; 2007 Jul 14; 9(4):575-84. PubMed ID: 17451425
    [Abstract] [Full Text] [Related]

  • 20. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.
    Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T, Vytorin Extension Study Group.
    Int J Clin Pract; 2007 Sep 14; 61(9):1469-80. PubMed ID: 17655686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.